
Claims

1. A liquid pharmaceutical composition comprising compound 1, or a pharmaceutically acceptable salt thereof.



Compound 1

and pharmaceutically acceptable carriers, wherein the carriers comprise ethanol, d-α-tocopheryl polyethylene glycol succinate (TPGS), and polyethyleneglycol.

2. The liquid pharmaceutical composition according to claim 1, wherein compound 1 is the L-malate salt (or S-malate salt).

3. The liquid pharmaceutical composition according to claim 1, wherein compound 1 is the D-malate salt (or R-malate salt).

4. The liquid pharmaceutical composition according to any one of claims 1-3, wherein the amount of compound 1, or a pharmaceutically acceptable salt thereof present in the liquid formulation, ranges from 1 mg to 200 mg.

5. The liquid pharmaceutical composition according to claim 4, wherein the amount of the compound of compound 1, or a pharmaceutically acceptable salt thereof present in the liquid formulation is 140 mg, or 120 mg, or 80 mg, or 60 mg, or 40 mg, or 20 mg.

6. The liquid pharmaceutical composition of claim 1, wherein the carriers comprise from 50% to 95% polyethyleneglycols (w/w), from 1% to 30% TPGS (w/w), and from 0.5% to 20% ethanol (w/w).


7. The liquid pharmaceutical composition of claim 1, as provided in any one of the following tables.

Ingredient	Theoretical Quantity (mg/unit dose)		
	20-mg Dose	40-mg Dose	60-mg Dose
Cabozantinib (S)-malate	25.34	50.68	76.02
Polyethylene glycol 400 (PEG 400)	2,934.88	5,869.77	8,804.65
d-α-tocopheryl polyethylene glycol succinate (TPGS)	345.28	690.56	1,035.84
Ethanol	172.64	345.28	517.92
Flavorings	3.45	6.91	10.36
Total	3,481.60	6,963.19	10,444.79

Ingredient	(% w/w)
Compound 1	0.73
Polyethylene glycol 400 (PEG 400)	84.30
d-α-tocopheryl polyethylene glycol succinate (TPGS)	9.92
Ethanol	4.96
Flavorings	0.10
Total	100

Ingredient	Theoretical Quantity (mg/unit dose)
Compound 1	175.00
Polyethylene glycol 400 (PEG 400)	20,268.53
d-α-tocopheryl polyethylene glycol succinate (TPGS)	2,384.53
Ethanol	1,192.27
Flavorings	23.85
Total	24,044.18

8. A liquid pharmaceutical composition for use in treating locally advanced or metastatic solid tumors, the liquid pharmaceutical composition comprising compound 1



Compound 1

or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable carriers comprise ethanol, d-α-tocopheryl polyethylene glycol succinate (TPGS), and polyethyleneglycol.

9. The liquid pharmaceutical composition for use according to claim 8, wherein compound 1 is to be administered as the L-malate salt (or S-malate salt).

10. The liquid pharmaceutical composition for use according to claim 8, wherein compound 1 is to be administered as the D-malate salt (or R-malate salt).

11. The liquid pharmaceutical composition for use according to any one of claims 8-10, wherein the locally advanced or metastatic solid tumors is advanced urothelial carcinoma or renal cell carcinoma.

12. The liquid pharmaceutical composition for use according to claim 8, wherein compound 1, or a pharmaceutically acceptable salt thereof is to be administered in a liquid dosage form once daily with fasting in an amount of 140 mg, 120 mg, 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg.

13. The liquid pharmaceutical composition for use according to claim 12, wherein compound 1, or a pharmaceutically acceptable salt thereof is to be administered in the liquid pharmaceutical composition once daily with fasting in an amount of 140 mg, 120 mg, 80 mg, 60 mg, 40 mg, or 20 mg.

14. The liquid pharmaceutical composition for use according to claim 8, wherein the carriers comprise from 50% to 95% polyethyleneglycols (w/w), from 1% to 30% TPGS (w/w), and from 0.5% to 20% ethanol (w/w).


15. The liquid pharmaceutical composition for use according to claim 8, wherein the liquid pharmaceutical composition is as provided in any one of the following tables.

Ingredient	**Theoretical Quantity (mg/unit dose)**		
	20-mg Dose	**40-mg Dose**	**60-mg Dose**
Cabozantinib (S)-malate	25.34	50.68	76.02
Polyethylene glycol 400 (PEG 400)	2,934.88	5,869.77	8,804.65
d-α-tocopheryl polyethylene glycol succinate (TPGS)	345.28	690.56	1,035.84
Ethanol	172.64	345.28	517.92
Flavorings	3.45	6.91	10.36
Total	3,481.60	6,963.19	10,444.79

Ingredient	**(% w/w)**
Compound 1	0.73
Polyethylene glycol 400 (PEG 400)	84.30
d-α-tocopheryl polyethylene glycol succinate (TPGS)	9.92
Ethanol	4.96
Flavorings	0.10
Total	100

Ingredient	**Theoretical Quantity (mg/unit dose)**
Compound 1	175.00
Polyethylene glycol 400 (PEG 400)	20,268.53
d-α-tocopheryl polyethylene glycol succinate (TPGS)	2,384.53
Ethanol	1,192.27
Flavorings	23.85
Total	24,044.18

16. Use of compound 1



Compound 1

in the manufacture of a liquid pharmaceutical composition for treating locally advanced or metastatic solid tumors, wherein the liquid pharmaceutical composition comprises compound 1 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable carriers comprise ethanol, d-α-tocopheryl polyethylene glycol succinate (TPGS), and polyethyleneglycol.

17. The use according to claim 16, wherein compound 1 is to be administered as the L-malate salt.

18. The use according to claim 16, wherein compound 1 is to be administered as the D-malate salt.

19. The use according to claim 16, wherein the carriers comprise from 50% to 95% polyethyleneglycols (w/w), from 1% to 30% TPGS (w/w), and from 0.5% to 20% ethanol (w/w).

20. The use according to any one of claims 16-19, wherein the locally advanced or metastatic solid tumors is advanced urothelial carcinoma or renal cell carcinoma.